亚太地区过敏反应治疗市场预测至 2028 年 - 按药物类型(肾上腺素、抗组胺药、类固醇、β 激动剂等)、给药途径(口服、肠胃外等)、过敏类型(食物)划分的 COVID-19 影响和区域分析过敏、药物、昆虫叮咬等)和分销渠道(医院药房、零售等)

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028


No. of Pages: 154    |    Report Code: TIPRE00023950    |    Category: Life Sciences

Asia Pacific Anaphylaxis Treatment Market

市场介绍

过敏反应是一种过敏反应,可进一步导致称为过敏性休克的致命疾病。当患者的身体对异物产生反应并产生大量组胺从而引发炎症反应时,就会发生过敏反应。这是一种严重的、危及生命的过敏反应,其症状包括吞咽和呼吸困难、皮肤瘙痒和血压降低。

因此,过敏反应发生率的上升预计将对过敏反应产生巨大的需求未来几年的治疗,预计这将进一步推动过敏反应治疗市场。

当然,COVID-19 会增加哮喘和过敏性疾病加重的风险,但政府和私人机构正在指导治疗。根据韩国哮喘、过敏和临床免疫学研究院以及韩国小儿过敏和呼吸系统疾病研究院的指导方针,需要对所有患有哮喘和过敏症的患者继续进行详细监测并使用 AIT、ICS 和生物制剂进行最佳治疗疾病。这可以在安全条件下使用最佳保护措施来实现。高风险患者(老年和合并症)应受到更严格的监测。在 COVID-19 大流行期间,所有致力于患者管理、努力保持最佳健康保护的过敏/免疫学专家都是必要的。随着亚太地区经历新冠肺炎 (COVID-19) 大流行的挑战时期,亚太过敏、哮喘和临床免疫学协会 (APAAACI) 作为过敏/免疫学界,通过其新冠肺炎 (COVID-19) 工作组正在仔细监测和更新食品和药物管理局的信息/疾病控制与预防中心/世卫组织以及其网站上的 COVID-19 资源部分上有关 COVID-19 的其他重要科学信息。因此,对过敏治疗的需求不断增长可能会提振市场。

 

 

市场概况和动态

亚太地区过敏反应治疗市场预计将从美元增长2021年为3.507亿美元,到2028年为6.64亿美元;预计 2021 年至 2028 年复合年增长率为 9.6%。过敏反应是一种严重的、危及生命的过敏反应,由易受过敏原(食物、昆虫叮咬或药物)引起,被确定为这种情况的典型症状包括吞咽和呼吸困难、皮肤发红和瘙痒、心率加快、喘息、呼吸频率加快和血压降低。世界范围内过敏反应的发生率正在增加。因此,过敏发生率的上升导致过敏反应病例激增,由于过敏患病率的不断上升,许多国家医疗保健系统的经济负担不断增加,因此,过敏反应发生率的迅速上升正在推动市场的增长。

 

主要细分市场

从药物类型来看,肾上腺素细分市场占2020年亚太过敏反应治疗市场份额最大。从给药途径来看,2020年亚太过敏反应治疗市场的最大份额为肠外给药。从过敏类型来看,食物过敏细分市场占2020年亚太过敏反应治疗市场的最大份额。 2020年亚太地区过敏反应治疗市场份额最大。从分销渠道来看,2020年零售药店在过敏反应治疗市场中占有较大的市场份额。

主要来源和上市公司

一些主要的一手和二手来源准备本亚太地区过敏反应治疗市场报告所参考的资料包括公司网站、年度报告、财务报告、国家政府文件和统计数据库等。报告中列出的主要公司包括 Amneal Pharmaceuticals Inc.、Mylan NV、Abbott、Pfizer Inc.、Glaxosmithkline Plc.、Merck and Co., Inc.、Teva Pharmaceutical Industries Ltd. 和 ALK-ABELLó。

< p>

 

购买报告的理由

  • 了解亚太地区过敏反应治疗市场格局并确定最有可能保证的细分市场强劲回报
  • 了解亚太过敏反应治疗市场不断变化的竞争格局,保持领先地位
  • 有效规划亚太过敏反应治疗市场的并购和合作交易通过识别最有希望销售的细分市场
  • 通过对亚太过敏反应治疗市场各个细分市场的市场表现进行敏锐和全面的分析,帮助做出明智的业务决策
  • 获得市场收入亚太地区2021-2028年各细分市场的市场预测

 

< strong>亚太地区过敏反应治疗市场细分

药物类型

  • 肾上腺素
  • 抗组胺药
  • 类固醇
  • β-激动剂
  • 其他

 

作者给药途径

  • 肠胃外
  • 口服
  • 其他

 

按过敏类型

  • 食物过敏
  • 药物
  • 昆虫叮咬
  • 其他

 

按分销渠道

  • 医院药房
  • 零售药房
  • 其他

 

按国家/地区

  • 亚太地区
      < li>中国
    • 日本
    • 印度
    • 韩国
    • 澳大利亚
    • 亚太地区其他地区

 

 

提及的公司

    < li>Amneal Pharmaceuticals Inc.
  1. Mylan NV
  2. 雅培
  3. 辉瑞公司
  4. 葛兰素史克公司
  5. 默克公司
  6. 梯瓦制药工业有限公司       
  7. ALK-ABELLó   ; 

 

 

Asia Pacific Anaphylaxis Treatment Strategic Insights

Strategic insights for Asia Pacific Anaphylaxis Treatment involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/asia-pacific-anaphylaxis-treatment-market-strategic-framework.webp
Get more information on this report

Asia Pacific Anaphylaxis Treatment Report Scope

Report Attribute Details
Market size in 2021 US$ 350.7 Million
Market Size by 2028 US$ 664.0 Million
Global CAGR (2021 - 2028) 9.6%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By 药物类型
  • 肾上腺素
  • 抗组胺药
  • 类固醇
  • β-激动剂
By 给药途径
  • 口服
  • 肠胃外
By 过敏类型
  • 食物过敏
  • 药物过敏
  • 昆虫叮咬
By 分销渠道
  • 医院药房
  • 零售
Regions and Countries Covered 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
Market leaders and key company profiles
  • Amneal Pharmaceuticals Inc.
  • Mylan N.V.
  • Abbott
  • Pfizer Inc.
  • Glaxosmithkline Plc.,
  • Merck And Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • ALK-ABELLó
  • Get more information on this report

    Asia Pacific Anaphylaxis Treatment Regional Insights

    The regional scope of Asia Pacific Anaphylaxis Treatment refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/asia-pacific-anaphylaxis-treatment-market-geography.webp
    Get more information on this report

    The List of Companies - Asia Pacific Anaphylaxis Treatment Market

    1. Amneal Pharmaceuticals Inc.
    2. Mylan N.V.
    3. Abbott
    4. Pfizer Inc.
    5. Glaxosmithkline Plc.,
    6. Merck And Co., Inc.
    7. Teva Pharmaceutical Industries Ltd.        
    8. ALK-ABELLó   
    Frequently Asked Questions
    How big is the Asia Pacific Anaphylaxis Treatment Market?

    The Asia Pacific Anaphylaxis Treatment Market is valued at US$ 350.7 Million in 2021, it is projected to reach US$ 664.0 Million by 2028.

    What is the CAGR for Asia Pacific Anaphylaxis Treatment Market by (2021 - 2028)?

    As per our report Asia Pacific Anaphylaxis Treatment Market, the market size is valued at US$ 350.7 Million in 2021, projecting it to reach US$ 664.0 Million by 2028. This translates to a CAGR of approximately 9.6% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Anaphylaxis Treatment Market report typically cover these key segments-

  • 药物类型 (肾上腺素, 抗组胺药, 类固醇, β-激动剂)
  • 给药途径 (口服, 肠胃外)
  • 过敏类型 (食物过敏, 药物过敏, 昆虫叮咬)
  • What is the historic period, base year, and forecast period taken for Asia Pacific Anaphylaxis Treatment Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Anaphylaxis Treatment Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in Asia Pacific Anaphylaxis Treatment Market?

    The Asia Pacific Anaphylaxis Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Amneal Pharmaceuticals Inc.
  • Mylan N.V.
  • Abbott
  • Pfizer Inc.
  • Glaxosmithkline Plc.,
  • Merck And Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • ALK-ABELLó
  • Who should buy this report?

    The Asia Pacific Anaphylaxis Treatment Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Anaphylaxis Treatment Market value chain can benefit from the information contained in a comprehensive market report.